Viatris Inc. acquires Pacira BioSciences, Inc. (2026)

Deal facts

Buyer: Viatris Inc.
Target: Pacira BioSciences, Inc.
Deal value: Not disclosed
Announced: 8 October 2026
Status: Firm intention
Sector: Healthcare
Country: United States
Consideration: cash

Sources

What we know

Viatris Inc. has agreed to acquire Pacira BioSciences, Inc. in a cash transaction that will take the target company private. The deal was announced on 8 October 2026 and involves a full cash offer for the equity of the healthcare firm. Both the acquirer and the target are based in the United States. The transaction is structured as a going private deal, meaning Pacira BioSciences will cease to be a publicly listed entity following the completion of the purchase. The consideration for the acquisition is entirely cash, with no equity component reported in the available data. No specific headline value or currency amount has been confirmed in the initial reporting, although the currency is identified as US dollars. The firm operates within the broader healthcare sector, focusing on specialized medical products. This move represents a significant shift for Pacira BioSciences, transitioning it from public markets to private ownership under Viatris. The transaction is currently at the firm intention stage, indicating a strong commitment to proceed, though it has not yet been completed. The process is subject to standard regulatory approvals and customary closing conditions.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates

8 Oct 2026Firm intention
Viatris Inc. firm intention to acquire Pacira BioSciences, Inc.
Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On October 8, 2026, Viatris Inc., a Delaware corporation (“Viatris”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary of Viatris (“Purchaser”). Pu
Source
8 Oct 2026Firm intention
Viatris Inc. firm intention to acquire Pacira BioSciences, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the “Company” or “Pacira”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris Inc., a Delaware corporation (“Parent”), and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”). Pursuant to the Me
Source

OpinionExit Mode editorial

We see the announcement that Viatris Inc. intends to acquire Pacira BioSciences, Inc. through a cash-only tender offer. Both parties are US-based and operate in the healthcare sector, so the deal will be governed primarily by US securities law and antitrust oversight. The tender-offer structure means the target’s shareholders will be asked to tender their shares at a set price, and the transaction will close once the required acceptance threshold is met. For founders, the key point is that a tender offer often triggers change-of-control clauses in existing contracts, which can accelerate repayment of debt or force renegotiation of supplier agreements.

From a strategic angle, the move signals a continued appetite for consolidation in the healthcare space, even as the market wrestles with pricing pressure and regulatory scrutiny. Viatris is likely seeking to broaden its product portfolio and enhance its distribution network, while Pacira’s specialised offerings could fill gaps in Viatris’s pipeline. The cash consideration, although undisclosed, suggests a willingness to fund the deal without diluting equity, a factor that can be attractive to investors but also raises the need for careful cash-flow planning post-close.

Regulatory risk is not negligible. In the United States, the FTC and DOJ will review the transaction for competition concerns, especially given the overlap in therapeutic areas. Although the deal is domestic, UK-based founders should note that similar cross-border transactions would attract a CMA review, potentially adding a layer of delay. Additionally, tender offers often include escrow arrangements to protect against post-closing adjustments, and any earn-out contingencies would be tied to performance milestones that could affect future payouts.

For an SME founder reading this, the practical takeaway is clear: if you are considering a sale or a strategic partnership, review all change-of-control provisions and antitrust thresholds now, and engage a legal adviser to model the cash-flow impact of any escrow or earn-out mechanisms. This week, schedule a brief call with your counsel to map those clauses against your current agreements.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More tender offer deals More from Viatris Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

14 October 2026Firm intentionHealthcare

Laboratory Corporation of America Holdings to acquire BioReference Health, LLC

Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 Oc…

Buyer: Laboratory Corporation of America Holdings
Target: BioReference Health, LLC
Deal value: USD 722,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

14 October 2026CompletedHealthcare

Silo Pharma, Inc. to acquire Larry King

Silo Pharma, Inc. has completed the acquisition of assets from Larry King. The transaction, which was announced on 14 October 2026, was finalized on 13 October 2026. Bot…

Buyer: Silo Pharma, Inc.
Target: Larry King
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

13 October 2026Firm intentionHealthcare

ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.

ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…

Buyer: ArcheNova Technology Co., Ltd
Target: ArcheNova Biotech Corp.
Deal value: USD 2,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals Cayman Islands deals

Buyer history

Viatris Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

Viatris Inc. to acquire Pacira BioSciences, Inc.